INK-055 (PI3Kγ inhibitor 1)

  Cat. No.:  DC7873  
Chemical Structure
1172118-03-4
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
INK055 is a dual PI3Kg/d inhibitor.
Cas No.: 1172118-03-4
Chemical Name: N-[6-[4-amino-1-[[8-methyl-2-(2-methylphenyl)-1-oxoisoquinolin-3-yl]methyl]pyrazolo[3,4-d]pyrimidin-3-yl]-1,3-benzothiazol-2-yl]acetamide
Synonyms: PI3Kγ inhibitor 1, AGN-PC-07162N, CHEMBL2216897, MolPort-027-836-537, AKOS016011504, AK120464, HY-10549
SMILES: O=C1N(C2=CC=CC=C2C)C(CN3N=C(C4=CC=C(N=C(NC(C)=O)S5)C5=C4)C6=C3N=CN=C6N)=CC7=CC=CC(C)=C71
Formula: C32H26N8O2S
M.Wt: 586.666
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: The dual PI3Kg/d inhibitor INK055 was effective as prophylactic therapy as well as in established arthritis. The modest effect on autoantibody production and benefit observed in established disease suggests that the mechanism is through an effect on innate immunity rather than antibody production. A dual specific PI3Kg/d inhibitor might be effective in rheumatoid arthritis while limiting systemic toxicity of a and b inhibitors. For the detailed information of INK-055, the solubility of INK-055 in water, the solubility of INK-055 in DMSO, the solubility of INK-055 in PBS buffer, the animal experiment (test) of INK-055, the cell expriment (test) of INK-055, the in vivo, in vitro and clinical trial test of INK-055, the EC50, IC50,and affinity,of INK-055, Please contact DC Chemicals.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC47385 PI3K-IN-23 PI3K-IN-23 is an (E)-9-oxooctadec-10-en-12-ynoic acid analogue to promote glucose uptake with an EC50 value of 7.00 μM.
DC47384 PI3Kγ inhibitor 5 PI3Kγ inhibitor 5 is an inhibitor of phosphoinositide 3-kinase γ (PI3Kγ) with an IC50 value of 34 nM.
DC47382 MCX 28 MCX 28, a triple PI3K/mTOR/PIM inhibitor, displays low nanomolar activity.
DC47088 Amdizalisib Amdizalisib is a PI3K inhibitor and used for the research of inflammatory disease, autoimmune disease or cancer.
DC46520 iMDK quarterhydrate iMDK quarterhydrate, a MDK-positive H441 and H520 lung adenocarcinoma cells inhibitor, suppresses the growth of H441 cells by inhibiting the PI3 kinase (PI3K) pathway and inducing apoptosis. iMDK quarterhydrate decreases MDK-induced migration, angiogenesis of endothelial cells and abrogats the progression and metastasis of NSCLC cells.
DC46457 PI3Kγ inhibitor 4 PI3Kγ inhibitor 4 is a potent, selective and orally active inhibitor of PI3Kγ, with an IC50 of 40 nM. PI3Kγ inhibitor 4 shows ∼7, 43, and 18-fold selectivity for PI3Kγ over the α, β, and δ isoforms, respectively. PI3Kγ inhibitor 4 can be used for the research of airway inflammation.
DC46384 PI3K-IN-19 hydrochloride PI3K-IN-19 hydrochloride is a phosphotidylinositol-3-kinase (PI3K) inhibitor extracted from patent WO2017153220, step 5.
DC46273 740 Y-P TFA 740 Y-P TFA is a potent and cell-permeable PI3K activator. 740 Y-P TFA readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone.
DC46266 PI3K-IN-20 PI3K-IN-20 is a PI3k inhibitor extracted from WO2017101847 A1, compound 1.
DC45823 AZ2 AZ2 is a highly selective PI3Kγ inhibitor. AZ2 can be used for the research of inflammatory and immune diseases.
X